Data investigation

The Old Cheap Drug Keeps Winning

A network meta-analysis of 41 pediatric trials found semaglutide producing the largest BMI reduction, and concluded an older, cheaper combination may be the better option.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·5 citations

A network meta-analysis of 41 trials in children and adolescents found semaglutide producing the largest reduction in BMI. Its authors nonetheless conclude that phentermine–topiramate, an older and cheaper combination, may be the optimal addition to lifestyle treatment.[1] The numbers underneath explain why, and they contain a discordance nobody accounts for.

The two ways of measuring disagree

The review pooled 41 randomized trials covering 3,923 children and adolescents, comparing drug treatments added to lifestyle modification against lifestyle modification alone. It reported both the average reduction and how many additional people crossed meaningful thresholds.

Against lifestyle modification alone. Reduction is in the 95th BMI percentile; responders are additional patients per 1,000 person-years.[1]
DrugMean reductionExtra reaching ≥5%Extra reaching ≥10%
Semaglutide−20.40% (95% CI −24.22 to −16.58)500399
Phentermine–topiramate−18.35% (−22.26 to −14.45)554734
LiraglutideSignificant, smaller——
ExenatideSignificant, smaller——
The larger average effect produced fewer people crossing the higher threshold.

At the 10% threshold, phentermine–topiramate produced nearly twice as many additional responders as semaglutide (734 against 399), even though its mean reduction was two percentage points smaller.

What that discordance implies, and what nobody explains

A larger mean with fewer responders is a statement about the shape of the distribution, not the size of the effect. It is what you get when one drug produces very large reductions in a subset while another produces moderate reductions in more people. The averages then favor the first while the threshold counts favor the second, and both are correct.

That is the most plausible reading, but it is not established. The review does not explain the pattern, and network meta-analyses can also generate discordant continuous and binary estimates for technical reasons: different studies contributing to different outcomes, different follow-up lengths, different definitions of response. We are reporting the discordance rather than resolving it.

It matters practically because the two measures answer different questions. “How much will the average child’s BMI fall” and “what are the chances this child gets a meaningful result” are not the same, and a family is usually asking the second.

The same drug came out ahead in adults, for a different reason

This is the second independent analysis to place phentermine–topiramate above semaglutide on a measure that is not raw efficacy. The American College of Physicians’ economic review found semaglutide to be low value compared with phentermine–topiramate in adults; that review is covered in we know what they do, not what they’re worth.

The two analyses differ in population, method and endpoint, yet they converge on the same underrated option. Neither analysis says the older drug produces more weight loss. Both say that once tolerability or cost enters the comparison, the ranking changes.

The pediatric reviewers make the tolerability point explicitly, citing it as the reason for their conclusion. Gastrointestinal side effects and discontinuation are the recurring cost of the GLP-1 class across the research on this site. In adolescents, where treatment may run for years and adherence is harder, that cost weighs more.

Why this is not a recommendation

Phentermine–topiramate is a stimulant combination with substantial contraindications of its own, including teratogenicity, which carries particular weight in adolescents who may become pregnant. It is not a gentler alternative; it is a different drug with a different risk profile (see how every FDA-approved appetite suppressant compares on its label), and choosing between them is a clinical decision about a specific young person. Taking phentermine alongside a GLP-1 is a separate question again, covered in phentermine and a GLP-1 together; phentermine on its own against a GLP-1 is in phentermine vs a GLP-1.
  • The outcome is BMI, not health. These are surrogate measures in a group whose outcomes lie decades away (see what changed in the teenagers’ bloodwork).
  • Long-term safety in growing bodies is unstudied for every drug here.
  • Not every drug here is FDA-approved for adolescents. Semaglutide, liraglutide and phentermine–topiramate are each labeled for obesity from age 12;[2][3][4] exenatide is not labeled for weight management.[5]
  • Trials in this population are small. With 3,923 participants across 41 trials, the average is fewer than a hundred per trial.

For what these drugs do to weight in adolescents specifically, see GLP-1 drugs in teenagers; for the diabetes question in the same age group, tirzepatide in ten- to seventeen-year-olds.

Frequently Asked Questions

Semaglutide produced the largest average reduction in the 95th BMI percentile, at 20.40% against lifestyle modification alone. But phentermine-topiramate produced more additional responders at both the 5% and 10% thresholds, and the reviewers conclude it may be the optimal adjunct because of tolerability.
It describes a different distribution: very large reductions in a subset against moderate reductions in more people. That is the most plausible reading, but the review does not explain the pattern, so it should be held loosely.
That is a clinical decision and this is not a recommendation. It is a stimulant combination with its own contraindications including teratogenicity. Like semaglutide and liraglutide, it is FDA-approved for adolescents 12 and older with obesity.
No. An independent economic review for the American College of Physicians found semaglutide low value compared with phentermine-topiramate in adults. The population and method differed; the underrated option was the same.
The review rests on forty-one trials covering 3,923 children, fewer than a hundred per trial on average. They measured BMI rather than health outcomes, and long-term safety in growing bodies is unstudied for every drug involved.

References

  1. 1.Luo L, Huang T, Yan Z, et al. Pharmacotherapy for Children and Adolescents With Overweight or Obesity: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials Diabetes, Obesity and Metabolism. 2026. PMID: 42310900.
  2. 2.VIVUS LLC QSYMIA (phentermine and topiramate extended-release) capsules, CIV — prescribing information (section 1, Indications and Usage) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40dd5602-53da-45ac-bb4b-15789aba40f9
  3. 3.Novo Nordisk SAXENDA (liraglutide) injection — prescribing information (section 1, Indications and Usage) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
  4. 4.Novo Nordisk WEGOVY (semaglutide) injection and tablets — prescribing information (section 1, Indications and Usage) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  5. 5.AstraZeneca Pharmaceuticals LP BYETTA (exenatide) injection — prescribing information (section 1, Indications and Usage) DailyMed, U.S. National Library of Medicine. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53d03c03-ebf7-418d-88a8-533eabd2ee4f

Tirzepatide in Ten- to Seventeen-Year-Olds

Youth-onset type 2 diabetes moves faster and responds worse than the adult disease. In 99 children aged 10 to 17, tirzepatide cut HbA1c by 2.23% while the placebo group's blood sugar rose.

6 min read

What Changed in the Teenagers' Bloodwork

A STEP TEENS analysis found insulin resistance down 35%, liver enzymes down 18%, and lipids improved in 12-to-17-year-olds. All of it is bloodwork, and the outcomes it stands in for are decades away.

7 min read

GLP-1 Drugs in Teenagers: What 18 Trials Show

Eighteen randomized trials in 1,402 children and adolescents with obesity, prediabetes or type 2 diabetes found improvements across every metabolic measure. Weight fell 3.02 kg more than on placebo, and the median treatment duration across all of them was half a year.

6 min read

We Know What They Do, Not What They're Worth

The American College of Physicians commissioned two reviews for one guideline. The efficacy review pooled 69 studies and reached clear conclusions. The cost review found nine, none at high certainty.

8 min read

The Weight Comparison Used 257 People

A 30,458-patient study reported surgery producing 28.3% weight loss against 10.3% on GLP-1s, at lower two-year cost. The cost half uses the whole cohort. The weight half uses 1.6% of one arm.

7 min read

The BMI Threshold Is Not Universal

Obesity is defined at BMI 30 in the US and at 25 in many Asian populations, because risk rises at lower body mass. Two phase 3 trials have now been run at those lower thresholds.

7 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.5

Gala

Moving between compounded and brand without changing seller

7.9

Luvo Health

Moving between compounded and brand without changing seller

6.3

WellMedRx

Comparing compounded and brand GLP-1 plans with a published state list

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →